Do you offer systemic therapy for NSCLC (no driver mutation) after resection of a metachronous solitary brain metastasis occuring after definitive therapy for limited disease, with no evidence of active extracranial disease?
Answer from: Medical Oncologist at Academic Institution
I'm not sure that I have any definitive evidence to present regarding this (ie no trial data), speaking primarily from experience and bias. As I take it, the patient presented in the question is now surgically NED and has had appropriate treatment of his isolated metastatic site of disease with no k...
Comments
Medical Oncologist at Intermountain Healthcare I generally agree with @Gregory A. Otterson, but w...
Medical Oncologist at Emory University School of Medicine Would you follow same rationale that @Gregory A. O...
Answer from: Medical Oncologist at Academic Institution
I agree with @Gregory A. Otterson's rationale and logic. This patient's greatest risk is for over-treatment (Dr. Otterson's #1 rationale above) and, in the setting of definite metastatic disease, I cannot rationalize exposing the patient to risk for, at best, uncertain benefit. Many patients, of cou...
I generally agree with @Gregory A. Otterson, but w...
Would you follow same rationale that @Gregory A. O...